New Drugs Update: Three Novel Treatments for SARS-CoV-2

Area of Science:

• Infectious Diseases
• Public Health
• Virology

Background:

• Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, emerged in late 2019.
• Over 530 million global cases and 6.2 million deaths reported by June 2022.
• All age groups are susceptible, with increased risk of severe illness and mortality in individuals aged 60 and older, long-term care residents, and those with chronic conditions.

Purpose of the Study:

• To summarize the global impact of SARS-CoV-2.
• To highlight risk factors for severe COVID-19 and mortality.
• To introduce available therapeutic options for mitigating severe outcomes.

Main Methods:

• Data compilation from global case reporting up to June 4, 2022.
• Analysis of demographic risk factors for severe illness and mortality.
• Review of emerging treatments including antivirals and monoclonal antibodies.

Main Results:

• Significant global burden of COVID-19 cases and deaths.
• Identified older age (≥60 years) and comorbidities as key risk factors for severe disease.
• Mortality risk is highest in patients over 70 years.
• Development and availability of COVID-19 testing, vaccines, antiviral treatments, and monoclonal antibodies.

Conclusions:

• COVID-19 remains a significant global health threat, particularly for older populations.
• Therapeutic interventions, including antivirals and monoclonal antibodies, are crucial for reducing severe disease progression and mortality.
• Continued vigilance and access to effective treatments are essential for managing the pandemic.